Clinical Diagnostics

The second edition of this report provides an overview of the digital pathology market from 2024 to 2029. The digital pathology market, as defined in this report, is comprised of revenue from instruments and software sold to clinical, academic, biopharma, and CRO customers, along with service revenues generated by CROs and reference labs.

Liquid biopsies (LBx), which, to-date, have been used largely for genomic profiling and therapy selection, are finding new applications throughout the patient journey and within pharma research. To help predict the future state of the market, we have developed an evaluation framework to identify and assess areas of growth within the liquid biopsy market.

DeciBio interviewed 10 biopharma leaders from the U.S. and EMEA to delve into the current usage, key applications, ROI, and unmet needs of AI/ML approaches in biopharma R&D, while also gathering insights on vendors used in the field.

The seventh edition of this report provides an overview of the life sciences research tools (LSRT) market from 2019 to 2027. LSRT companies offer instruments, reagents and services to academic, biopharma, applied market, and (non-IVD) clinical customers. While the LSRT space includes hundreds of companies, the market is relatively consolidated, with top vendors including Agilent, Becton Dickinson, Danaher, Illumina, Merck-EMD Millipore, and (most notably) Thermo Fisher representing the majority of sales; however, mid-size players (e.g., PacBio) and smaller emerging players (e.g., Element) are often growing more rapidly, and driving innovation.